Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Needham Keeps 'Buy' on Human Genome

Needham reiterates buy on Human Genome (HGSI ).

The FDA approved the drug maker's application for Albutropin, which analyst Carolyn Pratt says a long-acting form of human growth hormone -- meaning less frequent administration. Human Genome plans to begin with clinical studies in growth hormone deficient adults, and also is planning future trials in children. She says Human Genome differentiates itself from other gene companies in that it has put a continuous stream of drug candidates into clinical trials. She thinks Albutropin provides additional proof that Human Genome can continue to a build large, diverse pipeline. Pratt expects to hear more at Human Genome's investor meeting on Wednesday.

blog comments powered by Disqus